Manager TitleAgeSince
Investor Relations Contact - -
Corporate Officer/Principal - 10/04/2023
Date Insider Type Main position Quantity % Market Cap. Importance
10/04/23 Free

Executive/Senior Manager

4,00,000 0.6684%
01/02/23 Free

Chief Technology Officer

4,00,000 0.6686%
01/02/23 Free

Chief Operating Officer

4,00,000 0.6686%
Change 5-day change 1-year change 3-year change Capi.($)
-13.39%-23.18% - - 29.5L
+0.79%-6.46%+52.86%+71.34% 6.58TCr
+1.92%+10.35%+13.02%+87.74% 5.19TCr
+6.91%+8.57%+6.88%+72.12% 5.12TCr
+0.03%+3.23%+26.90%+45.96% 4.38TCr
+3.28%+9.33%+19.79%+131.00% 4.21TCr
+7.22%+3.50%+261.10%+597.28% 3.9TCr
-0.40%+9.42%+18.44%+59.06% 3.4TCr
+3.84%-4.94%+42.35%+8.92% 2.52TCr
+2.36%+5.34%+30.98%+26.07% 2.28TCr
Average +1.34%+0.51%+52.48%+122.17% 4.18TCr
Weighted average by Cap. +2.93%+0.62%+50.86%+124.03%
Logo Aravive, Inc.
Aravive, Inc. is a clinical-stage oncology company. The Company is focused on developing treatments designed to halt the progression of life-threatening diseases, including cancer and fibrosis. The Company's lead product candidate, Batiraxcept, is an ultra-high affinity decoy protein that binds to GAS6, the sole ligand that activates AXL, thereby inhibiting metastasis and tumor growth, and restoring sensitivity to anti-cancer agents. Batiraxcept has been granted Fast Track Designation by the United States Food and Drug Administration (FDA) for both clear cell renal cell carcinoma and platinum-resistant ovarian cancer and Orphan Drug Designation by the European Commission in platinum-resistant recurrent ovarian cancer. Batiraxcept is in an active registrational Phase III trial in platinum-resistant ovarian cancer (NCT04729608), a Phase Ib/II trial in clear cell renal cell carcinoma (NCT04300140), and a Phase Ib/II trial in pancreatic adenocarcinoma (NCT04983407).
Employees
23
  1. Stock Market
  2. Stocks
  3. ARAV Stock